Product Description: Iladatuzumab vedotin (DCDS-0780A) is an antibody–drug conjugate (ADC) containing humanized IgG1 anti-human CD79B monoclonal antibody (MCDS0593A; HY-P99656) conjugated to MMAE via a protease labile linker. Iladatuzumab vedotin uses novel THIOMAB technology (TDC) to consistently conjugate two MMAE molecules per antibody using engineered cysteine residues. Iladatuzumab vedotin has the potential for B-cell non-Hodgkin lymphoma (B-NHL) research[1].
Formula: N/A
References: [1]Alex F Herrera, et al. Anti-CD79B Antibody-Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study. Clin Cancer Res. 2022 Apr 1;28(7):1294-1301.